Eisai and CORE Biomedicine agree on global licence for oncology pipeline
Pharmaceutical Business Review
The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates.
pharminent
July 29, 2026 (Last updated: July 30, 2026)
Pharmaceutical Business Review
The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates.